Epithelial-To-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fiction or Fact?
Journal Title: Pancreas – Open Journal - Year 2016, Vol 1, Issue 1
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and lethal tumors, representing the fourth most common cause of cancer death in the Western world, with an estimated incidence of more than 40,000 cases per year in the United States. Despite continuous progress in imaging, surgical techniques, intensive care, and chemotherapeutic approaches, the current overall 5-year survival is less than 6%.1,2
Authors and Affiliations
Nicoletta Gagliano
Keywords
Related Articles
- EP ID EP556410
- DOI 10.17140/POJ-1-e001
- Views 164
- Downloads 0
Recurrent Acute Pancreatitis: Dangerous Etiology?
Acute pancreatitis (AP) is a disorder clinically characterized by upper abdominal pain and elevated levels of pancreatic enzymes in the blood.1 After an initial evaluation, up to 10-30% of patients with AP are diagnosed...
Epithelial-To-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fiction or Fact?
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and lethal tumors, representing the fourth most common cause of cancer death in the Western world, with an estimated incidence of more than 40,000 cas...
Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Despite significant effort and research funds, Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the deadliest diseases. This cancer is characterized by a distinct desmoplastic reaction that constitutes 80% of the t...
Ultrasound Ablation in Advanced Pancreatic Cancer Patients – What should be the Next Step?
In the last decades the treatment for many diseases has changed dramatically. Open surgery procedures with high morbidity and complication rates, suboptimal clinical results based on large impairment for the patients wer...
PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?
Programmed cell death protein 1 (PD-1), a member of the CD28 family, is an immune-checkpoint receptor expressed on a variety of immune cells, such as T-cells, monocytes, B-cells, dendritic cells, and tumor-infiltrating l...